<p><strong>Renal Impairment</strong>: The pharmacokinetics of Rifaximin in patients with impaired renal function has not been studied.<br />
<strong>Hepatic Impairment</strong>: The systemic exposure of Rifaximin was markedly elevated in patients with hepatic impairment compared to healthy subjects.</p>